Skip to main content
Erschienen in: Clinical Rheumatology 1/2011

01.03.2011 | Review

The burden of illness of rheumatoid arthritis

verfasst von: Annelies Boonen, Johan L. Severens

Erschienen in: Clinical Rheumatology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

It is necessary to understand the full burden of illness of a disease before the value of interventions can be assessed. Rheumatoid arthritis (RA) has an impact on a variety of stakeholders, including patients, healthcare systems, and society as a whole. This overview discusses the societal and patient perspectives, distinguishing several domains of impact. Epidemiology is important from a societal perspective, as it affects the total impact on health and costs related to RA and influences healthcare organization priorities. Co-morbidities, such as cardiovascular disease, are important factors contributing to the impact of RA. The impact on health is, naturally, relevant to both patients and society as a whole, and is summarized by health-related quality-of-life measures from the point of view of the patient and by utilities from the societal perspective. Similarly, work participation is important for both patients and society. Withdrawal from the labor force and short- and long-term sick leave are extensively studied in RA and lead to substantial productivity costs at the societal level and to income loss for patients. In addition, the recent concept of presenteeism, which reflects the problems that patients experience while at work, is considered. Finally, the costs of illness of RA are summarized. Societal costs are mainly driven by the costs of drug treatment and inpatient care, including surgery. Patient and family costs are mainly driven by the need for formal and informal care. Overall, RA has a significant impact on the health of and costs to patients and society, suggesting that effective interventions to reduce the impact are of value.
Literatur
1.
Zurück zum Zitat Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229PubMedCrossRef Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229PubMedCrossRef
2.
Zurück zum Zitat Chorus AM, Miedema HS, Boonen A, van der Linden S (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62:1178–1184PubMedCrossRef Chorus AM, Miedema HS, Boonen A, van der Linden S (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62:1178–1184PubMedCrossRef
4.
Zurück zum Zitat Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5:1–30PubMedCrossRef Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5:1–30PubMedCrossRef
5.
Zurück zum Zitat Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A (2008) Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 59:1018–1026PubMedCrossRef Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A (2008) Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 59:1018–1026PubMedCrossRef
6.
Zurück zum Zitat Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 60:1571–1582PubMedCrossRef Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 60:1571–1582PubMedCrossRef
7.
Zurück zum Zitat Geuskens GA, Burdorf A, Hazes JM (2007) Consequences of rheumatoid arthritis for performance of social roles—a literature review. J Rheumatol 34:1248–1260PubMed Geuskens GA, Burdorf A, Hazes JM (2007) Consequences of rheumatoid arthritis for performance of social roles—a literature review. J Rheumatol 34:1248–1260PubMed
8.
Zurück zum Zitat Wolfe F, Allaire S, Michaud K (2007) The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 34:2211–2217PubMed Wolfe F, Allaire S, Michaud K (2007) The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 34:2211–2217PubMed
9.
Zurück zum Zitat Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group (2004) Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 51:488–497PubMedCrossRef Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group (2004) Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 51:488–497PubMedCrossRef
10.
Zurück zum Zitat de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH (2004) Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 63:1362–1367PubMedCrossRef de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH (2004) Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 63:1362–1367PubMedCrossRef
11.
Zurück zum Zitat Mau W, Listing J, Huscher D, Zeidler H, Zink A (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32:721–728PubMed Mau W, Listing J, Huscher D, Zeidler H, Zink A (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32:721–728PubMed
12.
Zurück zum Zitat Chung CP, Sokka T, Arbogast PG, Pincus T (2006) Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 65:1653–1657PubMedCrossRef Chung CP, Sokka T, Arbogast PG, Pincus T (2006) Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 65:1653–1657PubMedCrossRef
13.
Zurück zum Zitat de Buck PD, de Bock GH, van Dijk F, van den Hout WB, Vandenbroucke JP, Vliet Vlieland TP (2006) Sick leave as a predictor of job loss in patients with chronic arthritis. Int Arch Occup Environ Health 80:160–170PubMedCrossRef de Buck PD, de Bock GH, van Dijk F, van den Hout WB, Vandenbroucke JP, Vliet Vlieland TP (2006) Sick leave as a predictor of job loss in patients with chronic arthritis. Int Arch Occup Environ Health 80:160–170PubMedCrossRef
14.
Zurück zum Zitat Björk M, Thyberg I, Rikner K, Balogh I, Gerdle B (2009) Sick leave before and after diagnosis of rheumatoid arthritis—a report from the Swedish TIRA Project. J Rheumatol 36:1170–1179PubMedCrossRef Björk M, Thyberg I, Rikner K, Balogh I, Gerdle B (2009) Sick leave before and after diagnosis of rheumatoid arthritis—a report from the Swedish TIRA Project. J Rheumatol 36:1170–1179PubMedCrossRef
15.
Zurück zum Zitat Walker N, Michaud K, Wolfe F (2005) Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 32:1006–1012PubMed Walker N, Michaud K, Wolfe F (2005) Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 32:1006–1012PubMed
16.
Zurück zum Zitat Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed
17.
Zurück zum Zitat Gilworth G, Chamberlain MA, Harvey A, Woodhouse A, Smith J, Smyth MG, Tennant A (2003) Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 49:349–354PubMedCrossRef Gilworth G, Chamberlain MA, Harvey A, Woodhouse A, Smith J, Smyth MG, Tennant A (2003) Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 49:349–354PubMedCrossRef
18.
Zurück zum Zitat Gilworth G, Emery P, Gossec L, Vliet Vlieland TP, Breedveld FC, Hueber AJ, Schett G, Tennant A (2008) Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). Ann Rheum Dis. doi:10.1136/ard.2008.098921 PubMed Gilworth G, Emery P, Gossec L, Vliet Vlieland TP, Breedveld FC, Hueber AJ, Schett G, Tennant A (2008) Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). Ann Rheum Dis. doi:10.​1136/​ard.​2008.​098921 PubMed
19.
Zurück zum Zitat Verstappen SM, Hoes JN, Ter Borg EJ, Bijlsma JW, Blaauw AA, van Albada-Kuipers GA, van Booma-Frankfort C, Jacobs JW (2006) Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis 65:1506–1511PubMedCrossRef Verstappen SM, Hoes JN, Ter Borg EJ, Bijlsma JW, Blaauw AA, van Albada-Kuipers GA, van Booma-Frankfort C, Jacobs JW (2006) Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis 65:1506–1511PubMedCrossRef
21.
Zurück zum Zitat Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, Severens JL (2005) Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 23:47–54 Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, Severens JL (2005) Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 23:47–54
22.
Zurück zum Zitat Wolfe F, Michaud K, Choi HK, Williams R (2005) Household income and earnings losses among 6, 396 persons with rheumatoid arthritis. J Rheumatol 32:1875–1883PubMed Wolfe F, Michaud K, Choi HK, Williams R (2005) Household income and earnings losses among 6, 396 persons with rheumatoid arthritis. J Rheumatol 32:1875–1883PubMed
23.
Zurück zum Zitat Westhovens R, Boonen A, Verbruggen L, Durez P, De Clerck L, Malaise M, Mielants H (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24:615–619PubMedCrossRef Westhovens R, Boonen A, Verbruggen L, Durez P, De Clerck L, Malaise M, Mielants H (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24:615–619PubMedCrossRef
24.
Zurück zum Zitat Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM, Arthritis Cost and Outcome Project Group (2002) Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 61:818–821PubMedCrossRef Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM, Arthritis Cost and Outcome Project Group (2002) Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 61:818–821PubMedCrossRef
25.
Zurück zum Zitat Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526PubMedCrossRef Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526PubMedCrossRef
Metadaten
Titel
The burden of illness of rheumatoid arthritis
verfasst von
Annelies Boonen
Johan L. Severens
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe Sonderheft 1/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1634-9

Weitere Artikel der Sonderheft 1/2011

Clinical Rheumatology 1/2011 Zur Ausgabe

Introduction

Introduction

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.